Compounded vs. brand-name GLP-1s: what TikTok gets wrong

What's this video probably claiming?

Based on the caption, hashtags, and the creator's apparent affiliation with a compounded medication provider (the discount code and referral link structure are textbook pharma-affiliate content), this video is almost certainly pitching compounded semaglutide or tirzepatide as a smart, affordable alternative to brand-name GLP-1 medications like Ozempic or Wegovy. The creator appears to be a licensed provider (the "glp" in the handle suggests GLP-1 specialist or similar credential), which adds an air of clinical authority. The framing of 'compounded or brand name' as a question strongly implies the answer will favor compounded, given the referral incentive attached. The 60-second approval promise and discount code suggest a telehealth platform with a streamlined, conversion-focused onboarding funnel, not a thorough clinical intake. That combination, a credentialed creator, a soft clinical question, and a hard sales CTA, is worth examining carefully.

What does the science actually show?

The clinical evidence for semaglutide and tirzepatide is substantial and specific to the branded, FDA-approved formulations. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 2.4 mg weekly semaglutide (Wegovy) produced 14.9% mean body weight loss over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg weekly produced up to 22.5% body weight reduction over 72 weeks. These outcomes were achieved with specific pharmaceutical-grade formulations, defined titration schedules, and monitored clinical protocols. Compounded versions of these drugs are not FDA-approved, have not been studied in large randomized controlled trials for efficacy or safety, and are not required to demonstrate bioequivalence to the branded drugs. The FDA has explicitly stated that compounded drugs are not FDA-approved and do not have the same safety and efficacy assurances. That is not a minor caveat.

Where does the social media noise diverge from clinical reality?

The biggest gap is the implied equivalency between compounded and brand-name GLP-1s. TikTok creators, even licensed ones, routinely present compounded semaglutide as essentially the same drug at a lower price. It is not. The FDA placed both semaglutide and tirzepatide on its shortage list, which temporarily allowed compounding pharmacies to produce copies under specific conditions. As of early 2025, the FDA declared the shortage of semaglutide resolved, which means most compounding of semaglutide is no longer legally permitted under the shortage exemption. This is a regulatory shift that many TikTok creators are either unaware of or not disclosing. A 60-second approval process also conflicts with established clinical guidelines. The Endocrine Society and obesity medicine specialists recommend thorough intake screening, contraindication review (pancreatitis history, thyroid conditions, eating disorders), and individualized dosing plans before initiating any GLP-1 therapy. Speed is a marketing feature, not a clinical one.

What should you actually know?

If you are considering a GLP-1 medication, a few things matter more than a discount code. First, verify that any telehealth provider uses licensed prescribers who conduct real medical reviews, not automated approvals. Second, understand that compounded GLP-1 medications carry regulatory uncertainty, and as the FDA resolves shortage designations, access to compounded versions may be restricted or eliminated entirely. Third, the impressive weight loss numbers from clinical trials reflect results under monitored conditions with specific dose titration over 68 to 72 weeks. Results in real-world, less-monitored settings are typically lower. A 2022 analysis by Ghusn et al. in Obesity Pillars found real-world semaglutide users lost around 5.9% of body weight at 3 months under standard care conditions, well below trial benchmarks. Finally, referral codes and affiliate links create financial incentives that can color clinical advice, even from licensed providers. That does not make every recommendation wrong, but it is context you deserve to have before you click.